{
  "docId": "019de074-2806-77f1-979f-2c5838bae35a",
  "docSlug": "7e995254b839b7fbb7e998df4127a7b8",
  "documentTitle": "ATAI | Investor Presentation Deck | 33 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 30,
  "pageCount": 33,
  "prevPage": 29,
  "nextPage": 31,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "The slide uses a checkmark-based comparison matrix to highlight the unique value proposition of DMX-1002.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-2806-77f1-979f-2c5838bae35a/30",
  "deckHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a",
  "deckJsonHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a.json",
  "deckAnchorHref": "/decks/019de074-2806-77f1-979f-2c5838bae35a#slide-30",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.2,
        "x": 0.05,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "DMX-1002 could potentially become a paradigm-shifting therapy for Opioid Use Disorder (OUD). Current standard of care for OUD is medication therapy, requiring opioid substitutes that carry significant side effects. Current strategies for withdrawal support have high rates of relapse",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28f4711b-e286-483e-a9ad-7a91183a41e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.26,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Note: OUD = Opioid Use Disorder. Source: Publicly available information, including company websites and clinicaltrials.gov, GlobalData, Evaluate Pharma (both as of 2022). 1. Current Standard of Care. 2. Rarely used given high rates of relapse. Used primarily in institutional or penitentiary settings",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d7ddbaf5-678e-4b68-997c-b528b4e9a706",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.7,
        "x": 0.26,
        "y": 0.21
      },
      "kind": "table",
      "text": "Comparison matrix of DMX-1002 vs Methadone, Buprenorphine, Naltrexone, Clonidine, Lofexidine across 5 criteria.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71b021a7-8471-4677-a59b-946232d360a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.26,
        "y": 0.07
      },
      "kind": "title",
      "text": "DMX-1002 has the potential to become the first & best in-class treatment for OUD, minimizing risk of relapse",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c9bbb16-e58d-43b3-ba09-f75f37671738",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "SUMMARY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e920cd60-2a21-408e-8f96-3312925f9427",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "d0406b16-5fe1-4215-a8d4-4e627e9df5b5",
      "evidence": "Comparison matrix of DMX-1002 vs Methadone, Buprenorphine, Naltrexone, Clonidine, Lofexidine across 5 criteria.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "47c1e572-9430-49d0-a772-4e07a62c795b",
      "evidence": "Competitive matrix comparing DMX-1002 against standard of care treatments.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 30,
      "from": 29,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "881a7577-25cc-41b7-b2fe-88ebe2283b82",
      "evidence": "The deck presents a sense of urgency, highlighting the potential for growth and innovation in the mental health space.",
      "position": 1,
      "objective": "Explain why now is the right time for atai Life Sciences' solutions",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}